News from halozyme therapeutics, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jul 22, 2014, 09:00 ET
Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.)

Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that it has resumed enrollment and dosing of patients in its ongoing Phase 2 trial...

Jun 25, 2014, 08:00 ET
Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.)

Roche's Commercial Launch Of MabThera SC Triggers Milestone Payment To Halozyme

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that the commercial launch of MabThera® SC in Europe has triggered a $5...

Jun 17, 2014, 16:30 ET
Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.)

Halozyme Therapeutics To Present At The JMP Securities 2014 Healthcare Conference

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the JMP Securities 2014 Healthcare Conference in New York, NY, on Tuesday,...

Jun 15, 2014, 15:00 ET
Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.)

Halozyme Announces Presentation Of Clinical Data At The American Diabetes Association 74th Scientific Sessions

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) today presented a scientific poster highlighting the CONSISTENT 1 trial results at the 74th...

Jun 04, 2014, 16:05 ET
Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.)

Halozyme To Resume PEGPH20 Clinical Program In Pancreatic Cancer

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on...

May 29, 2014, 16:30 ET
Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.)

Halozyme Therapeutics To Present At The Jefferies 2014 Global Health Care Conference

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Jefferies 2014 Global Health Care Conference in New York, NY, on...

May 14, 2014, 18:00 ET
Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.)

Halozyme Therapeutics To Present At The UBS 2014 Global Health Care Conference

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the UBS 2014 Global Health Care Conference in New York, NY, on Tuesday, May...

May 12, 2014, 16:15 ET
Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.)

Halozyme Reports First Quarter 2014 Financial Results

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the first quarter ended March 31, 2014. Financial...

May 07, 2014, 16:30 ET
Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.)

Halozyme Therapeutics To Present At The Bank Of America Merrill Lynch 2014 Health Care Conference

Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Bank of America Merrill Lynch 2014 Health Care Conference in Las Vegas,...

May 05, 2014, 17:00 ET
Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.)

Halozyme to Host first Quarter 2014 Financial Results Conference Call

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the first quarter 2014 on Monday, May 12,...

Apr 09, 2014, 08:00 ET
Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.)

Halozyme Announces Clinical Hold of PEGPH20 Pancreatic Cancer Trial Following Voluntary Halt of Trial by Halozyme

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the United States Food and Drug Administration (FDA) informed the company yesterday...

Apr 08, 2014, 09:00 ET
Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.)

Halozyme Announces Preclinical Data Presentations At The Association Of Cancer Research Annual Meeting

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that two scientific poster presentations on the pharmacology of PEGPH20 will be...

Apr 04, 2014, 08:00 ET
Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.)

Halozyme Announces Temporary Halt Of Phase 2 Trial Enrollment And Dosing For PEGPH20

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that as a result of a recommendation received yesterday from an independent Data...

Apr 02, 2014, 08:00 ET
Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.)

Halozyme Announces Appointment Of Oncology Product Team Leader And Other Executive Transitions

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the appointment of Sunil Joshi as Vice President and Global Product Team Lead...

Mar 31, 2014, 08:00 ET
Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.)

Halozyme Announces that Consistent 1 Trial Of Hylenex® Recombinant Met Primary Endpoint

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the primary endpoint of non-inferiority of A1C levels at six months was met for the...

Mar 28, 2014, 08:00 ET
Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.)

Halozyme Announces Roche Marketing Authorization For MabThera SC For Patients With Common Forms Of Non-Hodgkin Lymphoma In European Union

Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that the European Commission (EC) has approved Roche's new subcutaneous (SC) formulation...

Mar 25, 2014, 08:00 ET
Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.)

Halozyme Announces Positive Results From Phase 1/2 Clinical Trial In Cellulite With HTI-501

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced top-line data from a proof of concept Phase 1/2 clinical trial evaluating the use of...

Mar 05, 2014, 08:00 ET
Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.)

Halozyme Therapeutics To Present At The Barclays 2014 Global Healthcare Conference

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Barclays 2014 Global Healthcare Conference in Miami, FL on March 11, 2014...

Feb 27, 2014, 16:15 ET
Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.)

Halozyme Reports Fourth Quarter And Year End 2013 Financial Results

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the fourth quarter and full year ended December 31, 2013....

Feb 25, 2014, 16:15 ET
Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.)

Halozyme Therapeutics To Present At The Cowen And Company 34th Annual Healthcare Conference

Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Cowen and Company 34th Annual Healthcare Conference in Boston, MA on Tuesday,...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

ReportBuyer
Research and Markets
Investor-Edge